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                  With the emergence of new molecular biotechnologies, the inten-
sity of biomarker research has increased greatly, yet the scientific 
rigor of biomarker research lags far behind that of therapeutic 
research (  1    –    3  ). In therapeutic research, the randomized placebo-
controlled, blinded clinical trial takes the central role in pivotal 
evaluation of a new therapy. Standards for the conduct of such stud-
ies have been agreed upon internationally (  4  ) (  www.ich.org  ), and 
books and journals have been devoted to nuances of their design and 
analysis. Analogously, in this commentary, we consider key aspects 
of design for pivotal evaluation of a biomarker  ’  s capacity to correctly 
classify a subject’s outcome (ie, classification accuracy), in which a 
subject’s outcome may be his or her current disease status or a 
future event for him or her. We propose a prospective-specimen-
collection, retrospective-blinded-evaluation (PRoBE) design in 
which biologic specimens are collected prospectively from a cohort 
that represents the target population that is envisioned for clinical 
application of the biomarker. Specimens and clinical data are col-
lected in the absence of knowledge about patient outcome. After 
outcome status is ascertained, case patients with the outcome and 
control subjects without it are selected randomly from the cohort 
and their specimens are assayed for the biomarker in a fashion that 
is blinded to case  –  control status. Although every biomarker study 
has its own special considerations, as does every randomized clinical 
trial, we propose that elucidation of the key design issues in this 
commentary will help move the field toward standards of practice. 
  Biomarkers are developed for many different purposes, includ-
ing for classiﬁ  cation and prediction, as surrogate outcomes in clini-
cal trials, as measures of toxic or preventive exposures, or as a guide 
to individual treatment choice (  5  ). In this commentary, we con-
sider only the ﬁ  rst category, which includes diagnostic, screening, 
and prognostic markers. A diagnostic marker is used in people with 
signs or symptoms to aid in assessing whether they have a condi-
tion. A screening marker is used in asymptomatic people to detect 
a disease or condition at an early stage. A prognostic marker is used 
in subjects diagnosed with a condition to predict subsequent 
outcomes, such as disease recurrence or progression. The PRoBE 
design is intended for all of these applications. 
  Development of a biomarker is a process that begins with bio-
marker discovery, is followed by rigorous evaluation of classiﬁ  cation 
accuracy, and then terminates with the evaluation of the impact of 
the biomarker on clinical outcomes (  6  ,  7  ). Multiple studies may be 
involved in each stage. For example, in the discovery stage, a 
sequence of studies may be performed to identify biomarkers from 
among a large pool of candidates, to validate these individual mark-
ers in independent samples, and to optimally combine markers 
from a panel. We focus on the intermediate stage, after all discovery 
work is completed. We assume that a well-deﬁ  ned biomarker, or 
marker combination, is to be deﬁ  nitively evaluated for its classiﬁ  ca-
tion accuracy in a speciﬁ  c clinical application. If it can be shown that 
the marker has acceptable classiﬁ  cation accuracy, the marker should 
move to the ﬁ  nal stage of evaluation, in which the net beneﬁ  t to 
patients is assessed by incorporating effects of clinical interventions 
recommended for patients on the basis of their biomarker results. 
Clearly, before biomarker results are used in making medical deci-
sions for individuals, it is crucial to know how accurately the marker 
classiﬁ  es or predicts their outcomes. 
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    Components of the PRoBE Study Design 
  The PRoBE study design includes four key components. These 
components relate to clinical context and outcomes, criteria for 
measuring biomarker performance, the biomarker test itself, and 
the size of the study. Items pertaining to each of the components 
are listed in   Boxes 1    –    4  . 
    Clinical Context 
  For what population and in what clinical setting is the biomarker 
intended? The context for clinical application should drive the 
study design (  Box 1  ). Once the context has been defined, a random 
cohort of subjects from the target population is enrolled, pertinent 
clinical data are collected, and biologic specimens are collected and 
stored. A rigorous protocol for subject enrollment and specimen 
collection ensues. Generalizability of study results is an important 
consideration in pivotal evaluations, a concept that is well appreci-
ated in therapeutic clinical trials. This consideration motivates the 
design of a protocol that is simple enough for general use, that 
includes several institutions in the study, and that has inclusion and 
exclusion criteria that provide an adequately heterogeneous popu-
lation for the clinical application. 
            The outcome or condition that the biomarker is to classify 
must be deﬁ  ned and the procedures for evaluating it must be speci-
ﬁ  ed. These procedures may simply involve follow-up, or they may 
be invasive and/or costly. If procedures do not exist to measure the 
outcome of interest, study objectives may need to be modiﬁ  ed to 
use an alternative clinically relevant but measurable outcome (  8  ). 
  The purpose of the biomarker is to distinguish those with a bad 
outcome, whom we call case patients, from those with a good out-
come, whom we call control subjects. Case patients are those in 
whom we expect the biomarker to be positive, and control subjects 
are those in whom we expect the biomarker to be negative. 
Sometimes a positive biomarker result is deﬁ  ned as the absence or 
low level of that biomarker. Subgroups of case patients and control 
subjects may be of interest. For example, histology and disease 
stage can deﬁ  ne subgroups of cancer case patients. Benign disease 
and normal healthy organ tissue deﬁ  ne two subtypes of control 
subjects. All subjects in the target population must ﬁ  t into a pre-
cisely deﬁ  ned case or control category. 
  The design requires that random selections be made from the 
population for each category. In our experience, random selections 
of the relevant case patients and control subjects can be achieved 
only with a prospective cohort of subjects from the target popula-
tion, with collection and storage of specimens before determina-
tion of outcome. After outcome data become available (ie, when 
case or control designations are determined), random sets of case 
patients and control subjects are selected retrospectively and their 
specimens are retrieved from storage. 
  Classic confounding arises when case patients differ from con-
trol subjects on factors that are related to the biomarker and those 
factors are themselves predictive of disease. For example, case 
patients may be older than control subjects and, if the biomarker 
varies with age, some of the apparent difference in biomarker val-
ues between case patients and control subjects may simply be due 
to age discrepancies. Choosing control subjects to match case 
patients on such factors eliminates this sort of confounding. 
However, there are major disadvantages to matching that are not 
always appreciated (  9  ). First, matched control subjects are no lon-
ger representative of the control population, making interpretation 
of false-positive rates problematic. Second, a simple analysis that 
compares matched control subjects with case patients can attenu-
ate biomarker performance; that is, performance in the matched 
study as a whole appears worse than in subpopulations or strata in 
which matching factors are constant. Third, a matched study 
requires a covariate-adjusted analysis (  10  ), which is conceptually an 
analysis that stratiﬁ  es according to covariates. This is a disadvan-
tage because a stratiﬁ  ed analysis is more complicated to implement 
and interpret than an analysis that does not stratify by covariates. 
Interestingly, a matched design is most efﬁ  cient for this stratiﬁ  ed 
(ie, covariate-adjusted) analysis. 
  It should be noted that examining marker performance within 
covariate strata is not the same as including covariates in a statistical 
model for the outcome (  9  ,  10  ). The latter approach is concerned 
with performance of the combination of covariates and markers for 
classifying outcome. A serious problem with matching is that it 
actually precludes direct evaluation of the combination of markers 
and covariates. As a consequence, one cannot evaluate the incre-
ment in performance gained by combining a marker with the cova-
riates compared with the covariates alone for classiﬁ  cation.  In 
summary, one must carefully consider whether a covariate-stratiﬁ  ed 
    Box 1.     Components of design relating to clinical context. 
  Clinical Application
      
      •           Define the target population and clinical setting intended for 
use of the biomarker.   
      •           Define subject inclusion and/or exclusion criteria and process 
for enrollment.   
      •           Define the setting for specimen collection.   
      •           Ensure adequate generality in the population studied.     
      
  Outcome
      
      •           Define the outcome of interest.   
      •           Specify procedures for ascertaining and measuring the 
outcome.   
      •           Ensure prospective specimen collection before outcome 
ascertainment.     
      
  Case  –  Control Status
      
      •           Describe case patients (seek positive biomarker results in 
case patients) and subsets of case patients that are of interest.   
      •           Describe control subjects (seek negative biomarker results in 
control subjects) and subsets of control subjects that are of 
interest.   
      •           All subjects in the population must fit into a case or control 
category.     
      
  Selection
      
      •           Random selection of case patients and control subjects.   
      •           Consider matching of control subjects to case patients on 
factors related to the biomarker   only if   scientific questions 
of interest can be addressed with matched data. Be aware of 
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measure of performance is of primary interest in the clinical appli-
cation. If it is, then matching is recommended because of its statisti-
cal efﬁ   ciency. However, in many settings, a covariate-stratiﬁ  ed 
measure of performance will not be of primary interest, and the 
major complexities in the analysis that are introduced by matching 
indicate that it be avoided.   
    Performance Criteria 
  What do we want the biomarker to achieve? Performance criteria 
must be set to provide a yardstick for measuring the success or 
failure of the biomarker. The PRoBE design revolves around 
determining whether these criteria are met (  Box 2  ). 
            Performance measures and acceptable levels for these measures 
depend on clinical context. Consider ﬁ  rst the diagnostic setting, in 
which the biomarker is to identify people with disease as being 
positive. The true-positive rate and the false-positive rate are the 
typical performance measures of interest. Also known as the sensi-
tivity, the true-positive rate is the proportion of diseased people 
correctly detected as having disease by use of the marker. The 
false-positive rate (which equals 1      speciﬁ  city) is the proportion 
of nondiseased people incorrectly detected as having disease by use of 
the marker. Minimally acceptable values for both the true-positive 
rate and false-positive rate must be agreed upon at the design stage 
of the study. Current medical practice and effects of subsequent 
procedures or interventions resulting from positive and negative 
marker results impact on target values for true-positive rate and 
false-positive rate. 
  In a diagnostic study, the consequences of missing a case patient 
with invasive cancer may be fatal, which argues for a high true-
positive rate. For example, a biomarker might be developed to 
guide women with suspicious lesions for breast cancer to undergo 
biopsy examination or not (for details of this study conducted by the 
Early Detection Research Network, see Supplementary Material, 
available online). Women with invasive cancer that is, under cur-
rent protocols, detected with a biopsy examination should continue 
to be recommended for biopsy examination (ie, a very high true-
positive rate is required). However, under this current practice, the 
false-positive rate is 100%, in the sense that all women with suspi-
cious lesions who do not have invasive cancer are also subjected to 
biopsy examination. Study investigators consider that a reduction in 
the false-positive rate of even 25% would be beneﬁ  cial because it 
would result in 25% fewer women undergoing unnecessary biopsy 
examination. In other words, a false-positive rate of 75% is consid-
ered minimally acceptable by study investigators. 
  For general population screening, in contrast, the false-positive 
rate must be very low to avoid huge numbers of people undergoing 
unnecessary costly medical procedures. It has been argued that for 
ovarian cancer screening, the false-positive rate should not exceed 
2%. Because the goal of general population screening is to detect 
disease early, the proportion of case patients detected at some 
relevant time before the appearance of clinical disease is the appro-
priate true-positive rate performance measure; that is, the true-
positive rate is a function of the time lag between marker 
measurement and subsequent diagnosis of disease that would occur 
in the absence of screening. For example, detecting even 20% of 
invasive ovarian cancers at least 1 year before clinical diagnosis 
would be enormously beneﬁ  cial if such cancers could be success-
fully treated at that stage. Thus, the minimally acceptable false-
positive and true-positive rates in ovarian cancer screening might 
be a false-positive rate of at most 2% and a true-positive rate 
(1 year before clinical diagnosis of invasive disease) of at least 20%. 
  Performance criteria may vary with subgroups of case patients 
and control subjects. For example, the false-positive rate for 
women with normal ovaries should be at most 2%, but a much 
larger false-positive rate may be acceptable in control women with 
benign ovarian disease. One might require a higher true-positive 
rate for a disease histology that is likely to be successfully treated 
than for a disease that is not. 
  Performance criteria for prognostic markers bear similarities to 
those for screening markers. For example, the time between bio-
marker measurement and outcome must be considered. A bio-
marker may be more sensitive to outcomes, such as disease 
recurrence, that occur soon after marker measurement than to 
those that occur later. Moreover, it may be more important to 
identify subjects with subsequent events who are likely to be suc-
cessfully treated at the time the marker is measured. Patients with 
events occurring very soon after marker measurement may not 
beneﬁ  t. The false-positive rate is the fraction of control subjects 
with false-positive results. How do we deﬁ  ne control subjects for 
prognostic markers? A landmark time   T   after biomarker measure-
ment may be chosen as 1 year or 5 years, with control subjects 
    Box 2.     Components of design relating to performance criteria.  *   
  True- and False-Positive Rates
      
      •           Define TPR as the proportion of case patients with positive 
results.   
      •           Define FPR as the proportion of control subjects with positive 
results.   
      •           Does time between obtaining the specimen and the occur-
rence of an outcome impact on criteria for defining case 
subjects and control subjects? If so, provide corresponding 
time-dependent TPR and FPR definitions.   
      •           Are there subgroups of case patients and control subjects 
that are of interest? If so, will TPR and FPR be calculated 
separately for each subgroup? Which subgroups are of pri-
mary interest?     
      
  Minimally Acceptable Performance
      
      •           What are minimally acceptable values (or ranges) for the key 
TPR and FPR parameters in this clinical application?     
      
  Comparisons
      
      •           Does a classification method currently exist?   
      •           What is the performance of that method?   
      •           Will the biomarker alone be compared with the current 
classifier or will it be combined with the current method 
(ie, head-to-head comparison or evaluation of increment in 
performance)?   
      •           What are target levels for comparative performance of 
methods?     
      
    *    TPR = true-positive rate; FPR = false-positive rate.       jnci.oxfordjournals.org    JNCI | Commentary 1435
deﬁ  ned as those who are event free at time   T  . Subjects who die of 
other causes before time   T   or who have other catastrophic events 
are included in the main control group in this approach. An alterna-
tive approach is to consider those subjects as a second control group 
and to calculate two false-positive rates, one for subjects event free 
at time   T   (the main control group) and one for subjects who have 
other events before time   T   (the secondary control group). 
  Sometimes biomarkers and/or predictors already exist for the 
clinical application (eg, CA-125 for ovarian cancer screening). 
Comparisons with existing biomarkers must be part of the pivotal 
classiﬁ   cation accuracy study, and minimally acceptable improve-
ments in performance must be speciﬁ  ed. When there are difﬁ  culties 
or costs associated with existing markers, the goal may be to replace 
them with new markers. For example, pathologist assessment of 
nuclear grade of a ductal carcinoma in situ lesion is a marker for 
subsequent development of invasive breast cancer (  11  ). One would 
like to replace this marker with a biomarker that is cheaper, more 
reliable, and more transportable than expert pathology review. 
Head-to-head comparisons are appropriate in this setting. However, 
when existing biomarkers and/or predictors are easily obtained, the 
objective may be to assess the increment in performance that is 
achieved by adding the new marker to them. For example, the 
TRANSBIG prognostic breast cancer study (  12  ) found a relatively 
small increment in performance by adding the 70-gene signature to 
readily available data on clinical factors. Finally, if a marker is already 
part of standard clinical practice, it may be impossible to evaluate the 
inherent accuracy of a new marker. For example, because prostate-
speciﬁ  c antigen testing is routine in the United States, one can now 
evaluate only certain types of improvements that can be achieved by 
combining new markers with prostate-speciﬁ  c antigen for prostate 
cancer screening (  13  ) but not the performance of new markers used 
alone without prostate-speciﬁ  c antigen.   
    The Biomarker Test 
  What is the biomarker? It is defined in part by the biologic speci-
men, procedures and timing for specimen collection, processing, 
and storage, all of which must be detailed in the study protocol 
(  Box 3  ). For example, in the diagnostic breast cancer study, blood 
is drawn preoperatively and centrifuged at 4°C within 5 hours of 
collection, serum is removed by pipetting, and aliquots are stored 
at     80°C. The PRoBE design ensures that these procedures are 
blinded to the patient’s outcome status and to any information 
related to the outcome that is not available at the time of specimen 
collection. Retrieval of the specimen (eg, a serum aliquot) and 
the assay procedure itself must also be defined and blinded to 
outcome-related information. Blinding is a key component of the 
PRoBE design. Appropriate labeling of stored specimens ensures 
blinding. Only after the study is completed is the blinding broken 
so that outcome data can be linked with biomarker data. 
  Ideally, the assay used in the pivotal study should be the assay 
that is intended for general use. However, development of a com-
mercially available assay is not always practical before the pivotal 
study. The initial study may therefore use a research assay, with 
the recognition that, if the study is positive and an alternative assay 
is developed for widespread use, the alternative assay must be 
evaluated further, preferably with the same specimens that were 
used in the pivotal study. 
  It is now widely appreciated that the assessment of biomarker 
performance must be separated from biomarker discovery. In dis-
covery research, if a biomarker is selected from a set of candidates 
because of its apparent good performance, its performance in those 
samples is biased in an overoptimistic direction. This is a statistical 
phenomenon that reﬂ  ects elements of random variation in the par-
ticular samples chosen, specimen handling, and assay procedures. If 
the analysis were repeated with different specimens, the results 
would vary. The biomarkers that perform best in one dataset might 
not have the best performance in another. To estimate perfor-
mance without bias, an independent dataset is ideal. Therefore, in 
the pivotal evaluation, the topic of this commentary, the marker is 
deﬁ  ned in advance and no selection of markers is involved. 
  A biomarker test may be deﬁ  ned as a combination of several bio-
markers and possibly other predictors. The speciﬁ   c algorithm to 
combine the biomarker values into a score should be deﬁ  ned  in 
advance of the pivotal evaluation; that is, we regard development of a 
combination of several biomarkers as part of discovery and not part of 
the PRoBE design. Statistical techniques such as cross-validation or 
bootstrapping (  14  ) can sometimes be used to simultaneously discover 
and evaluate a marker combination, but these techniques require that 
all steps involved in developing the combination score be completely 
deﬁ  ned in advance, which is a tall order in practice. We and others 
(  1  ,  15  ) consider that instead a separate independent dataset is necessary 
to evaluate classiﬁ  cation accuracy. This dataset may be obtained by 
splitting a large dataset into two components, one for discovery  —  the 
training dataset  —  and one for pivotal evaluation  —  the test dataset. 
  A proﬁ  le of biomarker values over time may be more indicative of 
a subject’s outcome status than a single measurement. Accor  dingly, 
the biomarker test may be deﬁ  ned by an algorithm that combines the 
        Box 3.     Components of design relating to the biomarker. 
  Procedures
      
      •           Specify procedures for specimen collection, processing, stor-
age, and retrieval.   
      •           Specify assay procedures and how results are reported.     
      
  Blinding
      
      •           Are mechanisms in place to blind specimen handling, assay, 
and reporting of results to outcome status?     
      
  Combination
      
      •           Is the biomarker data to be combined with other information 
on the patient in the intended clinical application, including 
other clinical information, other markers, and previous mea-
surements of the biomarker in the patient?   
      •           The specific algorithm for calculating the combination must 
be defined (it cannot be developed during evaluation).     
      
  Other Biomarkers and Predictors
      
      •           If other biomarkers or predictors will be combined or com-
pared with the study biomarker, describe in detail protocols 
and procedures for obtaining these data.   
      •           Provide assurance that procurement of these items is blinded 
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subject’s historical and current biomarker values. For example, 
change from the average of two previous annual measurements could 
deﬁ  ne the biomarker test result. The schedule for specimen collec-
tion must give rise to sufﬁ  cient data for doing the calculation. In 
addition, because the manner in which the calculation is done 
amounts to deﬁ  ning how the current and historical biomarker data 
will be combined, the combination algorithm must not be derived 
during the pivotal evaluation but rather deﬁ  ned in advance of it.   
    Study Size 
  Conclusions must be drawn from the study. A positive conclusion 
is that the marker meets minimally acceptable performance criteria 
and a negative conclusion is that it does not (  Box 4  ). In practice, we 
calculate a confidence interval (or region) for the performance 
measure (or measures), which is a set of plausible values for the 
measure given the data, and draw a positive conclusion if all values 
in the interval are at least minimally acceptable. For example, in the 
diagnostic breast cancer study, the biomarker performance measure 
is the false-positive rate that corresponds to a true-positive rate of 
0.98  —  that is, the proportion of noncancers that are biomarker 
positive when we set the biomarker threshold to ensure that 98% 
of invasive cancers are positive. We would draw a positive conclu-
sion if, for example, the 95% confidence interval for the false-
positive rate was 0.50 to 0.60 because it indicates that while 
maintaining biopsy recommendations for at least 98% of invasive 
breast cancers only 50%  –  60% of noncancer lesions will continue to 
be recommended for biopsy examination. Proportions in this range 
are even better than the minimally acceptable value of 75% that 
was specified in the design. 
  At the design stage, when only pilot data or other information 
are available, we anticipate a desirable performance level for the 
biomarker and make sure that there is a high chance (or power) 
that a positive conclusion will be drawn from the study, if the true 
performance of the biomarker in the population is as good as is 
anticipated. These considerations give rise to procedures for sam-
ple size calculations. Note that a positive conclusion is expected 
only if the marker’s performance is better than minimally accept-
able (ie, at a desirable level). In statistical jargon, minimally accept-
able performance constitutes the null hypothesis that we wish to 
rule out, whereas the anticipated desirable performance level con-
stitutes the alternative hypothesis. We provide details of sample 
size calculations in the Supplementary Material (available online). 
  For an inherently dichotomous biomarker that is either positive 
or negative, one speciﬁ  es null (FPR  0  , TPR  0  ) and alternative (FPR  1  , 
TPR  1  ) values for the pair of performance measures, namely the 
false-positive rate and the true-positive rate. For a continuous bio-
marker, if some established threshold exists to deﬁ  ne a biomarker 
result as positive, then again null and alternative values for the 
false-positive and true-positive rates will be speciﬁ   ed for the 
dichotomized marker. More often, however, it will make sense 
either to set the false-positive rate at a minimally acceptable value, 
FPR  0  , and to estimate the corresponding biomarker threshold and 
true-positive rate from the pivotal study, or to set the true-positive 
rate at a minimally acceptable value, TPR  0  , and to estimate the cor-
responding biomarker threshold and false-positive rate from the 
pivotal study, as in the breast cancer study (Supplementary 
Material, available online). For the former, null (TPR  0  ) and alter-
native (TPR  1  ) true-positive rates are speciﬁ  ed and then sample sizes 
are calculated. In addition, one must ensure that the actual false-
positive rate associated with the estimated threshold is close 
enough to the target false-positive rate value, FPR  0  , which places 
further constraints on the number of control subjects, as described 
in the Supplementary Material (available online). For the latter, 
sample sizes are based on speciﬁ   ed null (FPR  0  ) and alternative 
(FPR  1  ) false-positive rates, and further requirements on the num-
ber of case subjects are made to ensure that the actual true-positive 
rate associated with the estimated threshold is close enough to the 
target value, TPR  0  . 
  Sample size formulas that are detailed in the Supplementary 
Material (available online) specify the numbers of case patients and 
control subjects required. However, specimen collection is performed 
for a cohort. The formulas will therefore be used in conjunction with 
projected prevalence or incidence rates in the cohort to calculate total 
numbers of subjects to be enrolled. Adjustments may be necessary if 
the actual rates are found to be different from those projected. 
  It is sometimes reasonable to terminate a study early if the analy-
sis of partially accumulated data indicates that the biomarker has 
poor performance. Data monitoring is commonplace in therapeutic 
research, in which ethical concerns motivate early termination (  16  ). 
In biomarker research, evaluation often begins after the cohort is 
assembled and specimens are stored; therefore, ethical concerns do 
not motivate early termination. However, preservation of specimens 
and resources is important. Therefore, if initial results show clearly 
that a biomarker has poor performance, the study should terminate. 
Otherwise, the study should continue so that estimates of perfor-
mance are reﬁ  ned. Standards of practice for study design in thera-
peutic research (  16  ) stipulate that early termination rules be 
speciﬁ  ed in advance. The same practice should be followed in bio-
marker research. One simple rule is to terminate at a preplanned 
data monitoring point if the 95% conﬁ  dence interval for biomarker 
performance is below minimally desirable levels. One must be cog-
nizant that allowing studies to terminate early causes bias in 
estimates of biomarker performance from studies that do not actu-
ally terminate early. Statistical methods to adjust for this bias are 
available (  17  ).   
    Box 4.     Components of design relating to study size. 
  Null Hypothesis
      
      •           Recall minimally acceptable performance criteria (  Box 2  ).     
      
  Alternative Hypothesis
      
      •           Define anticipated performance levels.   
      •           Provide rationale preferably with evidence from pilot data.     
      
  Sample Size
      
      •           Calculate case and control sample sizes (see Supplementary 
Material, available online).   
      •           Plan for prospective collection from a cohort until sufficient 
numbers of case patients and control subjects are enrolled.     
      
  Early Termination
      
    •             Plan for early termination of the study if appropriate.         jnci.oxfordjournals.org    JNCI | Commentary 1437
    Alternative Designs and Strategies 
  The most common bias in biomarker research involves systematic dif-
ferences in subject selection and/or specimen collection between case 
patients and control subjects. For example, specimens collected from 
case patients at a treatment center will differ from those collected from 
healthy control subjects at a blood donation center because of such 
factors as differences in specimen processing protocols, stress levels, 
and medication use. The prospective uniform nature of specimen col-
lection for all subjects from a single cohort in the PRoBE design elimi-
nates these systematic biases by ensuring that specimens for case 
patients and control subjects are collected in exactly the same way. 
  Another common problem is that the population or clinical set-
ting that is studied is not the setting for which the biomarker is 
intended. Performance of a biomarker in one setting may not reﬂ  ect 
performance in the setting of interest. The PRoBE design avoids 
this extrapolation bias (  18  ) by requiring that the clinical application 
be deﬁ  ned and that the study cohort be a random sample from the 
target population. Inclusion of several institutions in the study 
increases conﬁ  dence that the results generalize across institutions. 
  Simple retrospective case  –  control studies are notorious for spec-
trum bias (  18  ). A classic example is when selected case patients tend 
to have more severe or well-documented disease and selected control 
subjects are especially healthy, leading to overoptimistic estimates of 
biomarker performance. The PRoBE design avoids spectrum bias by 
identifying all subjects in the cohort as either case patients or control 
subjects and drawing randomly from the subgroups. Another prob-
lem with retrospective studies is that knowledge of the subject’s 
outcome status may affect the interpretation of an assay result or the 
care with which the specimen is handled. This bias is avoided in the 
PRoBE design by storing specimens before outcome ascertainment 
and by blinding specimens for retrieval and assay procedures. 
  In strictly prospective studies, the biomarker value is ascertained 
for all subjects in a cohort and outcome status is determined subse-
quently. These studies are also subject to problems. First, they cost 
more because all samples are assayed instead of only a case  –  control 
subset. Second, ethical problems arise when the biomarker value is 
known but there is uncertainty about how it should affect patient 
care. Overtreatment is one such ethical concern that has been real-
ized in the context of prostate cancer screening with prostate-
speciﬁ   c antigen testing. The retrospective component of the 
PRoBE design avoids this ethical dilemma. Third, if outcome ascer-
tainment is expensive or invasive, subjects with certain biomarker 
values may be more likely than those with other values to have the 
outcome ascertained. Incomplete ascertainment of outcome intro-
duces veriﬁ  cation bias, which typically inﬂ  ates both true- and false-
positive rates. Fourth, knowledge of the biomarker value may 
inﬂ  uence aspects of outcome determination, also leading to bias. 
The PRoBE design avoids all of these biases by ascertaining the 
outcome in a uniform manner for all subjects in the cohort and by 
timing biomarker measurement to occur after outcome assessment. 
  A major concern in biomarker research is overﬁ  tting bias. This 
bias occurs when a biomarker combination is evaluated with the 
same dataset that was used to develop it. By requiring completion of 
all discovery work before the pivotal evaluation, including develop-
ment of marker combinations, the PRoBE design avoids overﬁ  tting 
bias. When the pivotal evaluation study is constituted as the test set 
derived from a larger study that is split into training and test com-
ponents, the sample size calculations for the PRoBE design pertain 
to the size of the test component only. The threshold for marker 
positivity may or may not be deﬁ  ned in advance of the PRoBE study. 
If the threshold is derived from clinical settings that differ from the 
target setting or is derived from small studies, it is unwise to use that 
threshold. In contrast to previous approaches (  19  ), the PRoBE 
design accommodates estimation of the threshold in its sample size 
recommendations. Moreover, our approach to sample size calcula-
tion guarantees a certain power to rule out tests with unacceptable 
performance. This feature differs from approaches that are based 
simply on estimating performance with speciﬁ  ed precision (  19  ).     
    Discussion 
  In this commentary, we have presented guidance on the design of a 
biomarker accuracy study. Many of the principles have been high-
lighted elsewhere (  18  ,  19  ) but a comprehensive design has not, to our 
knowledge, been detailed heretofore. The design is ideal but strict 
adherence to it may be difficult or impossible in some circumstances. 
For example, the target population for screening markers is the 
general population but subjects that enroll in research studies may 
not be representative of the general population. The design requires 
specification of minimally acceptable values for measures of biomarker 
performance such as true- and false-positive rates. However, it does 
not provide guidance on how to arrive at these values. Expertise in 
techniques of medical decision making (  20  ) should play a major role 
in developing performance criteria that biomarkers should meet. 
  The design issues outlined in this commentary also have impli-
cations for biomarker discovery studies (  1  ). To avoid bias and 
make best use of resources, discovery studies should use key ele-
ments of the PRoBE design, including randomized selection of 
case patients and control subjects from a well-deﬁ  ned prospective 
cohort that is relevant to the intended clinical application, rigorous 
protocols that precisely deﬁ  ne data items and procedures to mea-
sure them, and mechanisms to ensure that biomarker and outcome 
assessments cannot inﬂ   uence each other. Nested case  –  control 
studies as described in this commentary would improve the quality 
of discovery research and increase the chances that truly valuable 
biomarkers will undergo deﬁ  nitive evaluation. One should ideally 
perform the pivotal PRoBE evaluation study for biomarkers that 
show promise in discovery studies that use the same clinical con-
text and population. Simultaneous discovery and evaluation of the 
per  formance of a marker or marker combination can be under-
taken by using a PRoBE design and randomly splitting the dataset 
into a training set for discovery and a test set for evaluation (  19  ). 
  We propose the PRoBE design to evaluate diagnostic, prognos-
tic, and screening biomarkers. In a previous study (  6  ) pertaining 
only to screening markers, we outlined ﬁ  ve phases for biomarker 
development. We observed that discovery studies often use conve-
nient samples that do not satisfy the criteria described in this com-
mentary. However, biomarker discovery has been plagued by false 
discoveries. Therefore, we now strongly encourage investigators to 
use population  –  science principles in the design of biomarker discov-
ery studies too (  21  ). The ﬁ  ve-phase paradigm also proposed that the 
phase 2 study, which analyzes specimens collected from case patients 
at the time of their clinical diagnosis, could precede the pivotal 1438   Commentary | JNCI  Vol. 100, Issue 20  |  October 15, 2008
phase 3 study, which uses specimens collected from case patients 
before clinical diagnosis. The rationale was that phase 2 studies can 
provide preliminary evidence to convince owners of repositories to 
part with precious preclinical specimens for phase 3 studies that 
concern early detection of disease. However, the current research 
environment is much more conducive to biomarker research than it 
was in the past, and in some settings preclinical specimens are readily 
available. In these settings, one should skip phase 2 and use preclini-
cal specimens for discovery work. This strategy is in keeping with 
the PRoBE design principle of using specimens that are directly 
relevant to the clinical application intended for the biomarker. 
  Repositories of specimens that can be used to evaluate biomark-
ers will greatly assist research in this ﬁ  eld (  22  ). In addition to hav-
ing specimens available for researchers, repositories facilitate 
combining and comparing markers that are proposed by different 
groups and/or at different times, which allows research to proceed 
in a uniﬁ  ed rather than a piecemeal fashion. Use of existing reposi-
tories from large observational or prevention studies is enabling 
research on markers for screening. Creation of additional biore-
positories is crucial as the discovery and evaluation of biomarkers 
for use in clinical medicine becomes a national research priority. 
The value of repositories for biomarker evaluation relies on careful 
attention to the design of studies that will be conducted with the 
stored specimens. In creating repositories, we urge adherence to 
the elements of the PRoBE design as a way of maximizing their 
value.   
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